Hikal Limited is an Indian fine chemicals and CDMO company supplying APIs, advanced intermediates, crop protection actives, animal health APIs and specialty chemicals globally, operating five manufacturing sites and an R&T centre with a focus on contract development and manufacturing services for global innovators and customers across Americas, Europe, Japan, LATAM and RoW.

Q3 FY26 marked a clear operational recovery for Hikal Limited after regulatory remediation: consolidated revenue recovered to INR494 crore and EBITDA expanded to INR83 crore, driven by resumed pharmaceutical supplies, improved capacity utilization and remediation largely completed at the inspected facility, restoring near‑term commercial momentum.

Strategic investments made over the past 12–18 months — including a High‑Potency API (HPAPI) laboratory, a new pilot plant and two multipurpose facilities — are now operational, materially enhancing Hikal Limited’s differentiated CDMO positioning for oncology and other high‑barrier small molecules and improving medium‑term revenue visibility.

The Crop Protection division faces structural pricing pressure from China and global overcapacity, prompting Hikal Limited to accelerate portfolio diversification into Personal Care and Specialty Chemicals (HiZenn, HiFend) with commercialisation expected to meaningfully contribute to revenues in FY27 and beyond.

Balance sheet and cash flows show improving discipline: 9M FY26 operating cash generation remained robust despite a temporary P&L impact from a one‑time labour code exceptional item, with targeted, contract‑led capex and a management commitment to reduce net debt as operating leverage returns.